Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00067548 | Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer | PHASE2 | COMPLETED | 44 | — | — | - | Jan 1, 2005 | Aug 21, 2009 | - | — |
| Name | Type | Description |
|---|---|---|
| EKB-569 | DRUG | - |
Inclusion Criteria: * Signed and dated, institutional review board (IRB) or independent ethics committee (IEC)-approved informed consent form before any protocol-specific screening procedures * Histologic and/or cytologic diagnosis of locally-advanced or metastatic non-small cell lung cancer in sub...